Kalaris 2025 loss narrows, cash runway to 2027

Kalaris Therapeutics reported a narrower full-year 2025 net loss of $43.4 million, improved from $69.2 million in 2024, as it advanced its lead retinal drug candidate TH103.

Rhea-AI Filing Summary

Kalaris Therapeutics reported a narrower full-year 2025 net loss of $43.4 million, improved from $69.2 million in 2024, as it advanced its lead retinal drug candidate TH103.

Cash, cash equivalents and marketable securities rose to $118.0 million as of December 31, 2025, from $1.6 million a year earlier, driven by its March 2025 merger with AlloVir and an oversubscribed $50.0 million private placement in December. The company expects this cash to fund operations into the fourth quarter of 2027.

Research and development expenses fell to $30.8 million from $45.0 million, largely reflecting a prior-year royalty obligation, while general and administrative costs increased to $15.4 million from $6.7 million as Kalaris scaled public-company infrastructure. Shares outstanding were 22,902,418 as of December 31, 2025.

Clinically, Kalaris reported positive initial Phase 1a single ascending dose data in neovascular age-related macular degeneration, noting TH103 was generally well tolerated with no dose-limiting toxicities or treatment-related serious adverse events. An ongoing Phase 1b/2 multiple ascending dose trial began enrolling in 2025, with preliminary data expected in the first half of 2027, and the company intends to start Phase 3 trials by year-end 2027.

Insights

Biopharma equity analyst

Kalaris improved its 2025 loss profile, strengthened cash, and advanced TH103 with encouraging early safety data.

Kalaris Therapeutics cut its 2025 net loss to $43.4 million from $69.2 million, while total operating expenses declined to $46.2 million. Lower research and development spending reflected a one-time 2024 royalty obligation, partly offset by higher clinical and manufacturing costs for TH103.

Cash, cash equivalents and marketable securities increased dramatically to $118.0 million as of December 31, 2025, helped by the merger with AlloVir and an oversubscribed $50.0 million private placement. Management states this should fund operations into the fourth quarter of 2027, covering several planned clinical milestones.

On the pipeline side, initial Phase 1a data in neovascular age-related macular degeneration showed TH103 was generally well tolerated, with no dose-limiting toxicities or treatment-related serious adverse events, and pharmacokinetics consistent with prolonged intraocular residence. An ongoing Phase 1b/2 trial is enrolling, with preliminary data anticipated in the first half of 2027, and Phase 3 trials are intended by year-end 2027. Future disclosures will clarify whether subsequent data support those development plans.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How did Kalaris Therapeutics (KLRS) perform financially in 2025?

Kalaris reported a 2025 net loss of $43.4 million, an improvement from a $69.2 million loss in 2024. Total operating expenses fell to $46.2 million, reflecting lower research and development costs after a large 2024 royalty expense, partially offset by higher public-company overhead.

What is Kalaris Therapeutics’ cash position and runway after 2025?

As of December 31, 2025, Kalaris held $118.0 million in cash, cash equivalents and marketable securities. Management expects this balance to fund operations into the fourth quarter of 2027, supporting ongoing and planned clinical trials and general corporate activities over that period.

What clinical progress did Kalaris Therapeutics (KLRS) report for TH103?

Kalaris reported positive initial Phase 1a single ascending dose data in neovascular age-related macular degeneration, with TH103 generally well tolerated and no dose-limiting toxicities or treatment-related serious adverse events. An ongoing Phase 1b/2 multiple ascending dose trial began enrolling in 2025 to further evaluate safety and dosing.

When will more TH103 clinical data be available and what are the next steps?

Kalaris expects preliminary data from the ongoing Phase 1b/2 TH103 study in the first half of 2027. The company also states it intends to initiate Phase 3 clinical trials by year-end 2027, assuming results continue to support further development in retinal diseases.

How did operating expenses change for Kalaris Therapeutics in 2025?

Research and development expenses declined to $30.8 million in 2025 from $45.0 million in 2024, mainly due to a large prior-year royalty obligation. General and administrative expenses increased to $15.4 million from $6.7 million as Kalaris expanded insurance, legal, accounting and personnel to support being public.

What financing activities supported Kalaris Therapeutics’ 2025 cash increase?

Kalaris’ cash growth to $118.0 million was primarily driven by completing its merger with AlloVir in March 2025 and closing an oversubscribed $50.0 million private placement in December 2025. These transactions strengthened the balance sheet and extended the company’s projected operating runway.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/17/2026 - 08:08 AM Learn about SEC filing dates

false 0001754068 0001754068 2026-03-17 2026-03-17

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 17, 2026

KALARIS THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

Delaware		001-39409		83-1971007
(State or other jurisdiction of incorporation)		(Commission File Number)		(I.R.S. Employer Identification No.)

Kalaris Therapeutics, Inc.

400 Connell Drive, Suite 5500

Berkeley Heights, New Jersey 07922

(Address of principal executive offices, including zip code)

(650) 249-2727

(Registrant’s telephone number, including area code)

Not applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.0001 par value per share		KLRS		The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On March 17, 2026, Kalaris Therapeutics, Inc. (the “Company”) issued a press release announcing the Company’s financial results for the year ended December 31, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The information in this Form 8-K, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filling.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
99.1		Press Release issued by Kalaris Therapeutics, Inc. on March 17, 2026
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

				KALARIS THERAPEUTICS, INC.
Date: March 17, 2026				By:		/s/ Andrew Oxtoby
				Name:		Andrew Oxtoby
				Title:		Chief Executive Officer

Exhibit 99.1

Kalaris Reports Full Year 2025 Financial Results and Provides Business Updates

Positive initial data reported from Phase 1a Single Ascending Dose study in nAMD in December 2025;

preliminary data from ongoing Phase 1b/2 study expected in 1H 2027

Intend to initiate Phase 3 clinical trials by year-end 2027

Completed oversubscribed $50.0 million private placement in December 2025

$118.0 million in cash, cash equivalents and marketable securities as of December 31, 2025 is expected to

fund operations into the fourth quarter of 2027 and through key clinical milestones

BERKELEY HEIGHTS, N.J., March 17, 2026 (GLOBE NEWSWIRE) - Kalaris Therapeutics, Inc. (Nasdaq: KLRS) (“Kalaris”), a clinical stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases, today announced financial results for the full year ended December 31, 2025 and provided business updates.

“This past year was truly transformational for Kalaris,” said Andrew Oxtoby, Chief Executive Officer of Kalaris Therapeutics. “Following our initial listing as a public company in March 2025, we continued to advance our clinical program for TH103 throughout the year, culminating with the disclosure of positive initial Phase 1a single ascending dose data and concurrent oversubscribed private placement. In Q3 2025, we began to enroll patients in our Phase 1b/2 multiple ascending dose trial which is designed to accelerate TH103’s clinical development and inform dose selection for potential future Phase 3 development.”

Q4 2025 - Business Updates

• Positive initial Phase 1a data reported in December 2025. The Phase 1a study evaluated a single intravitreal injection of TH103 at three dose levels (0.5 mg, 1.5 mg, 2.5 mg) in treatment-naïve nAMD patients. Thirteen patients completed 6 months of follow-up. Results demonstrated clinical activity on visual acuity and retinal anatomy, as well as pharmacokinetic data that support TH103’s molecular design and preclinical profile, including:

• Mean 10-letter best corrected visual acuity (BCVA) improvement

• Mean 129µm improvement in central subfield thickness (CST)

• Mean ~95% reduction in central subfield intraretinal fluid

• 27 to 51-fold lower mean plasma Cmax than current leading approved anti-VEGF agents

TH103 was generally well-tolerated and that data supported further dose escalation. No dose-limiting toxicities or treatment-related serious adverse events were observed in the Phase 1a study.

TH103’s initial pharmacokinetic profile aligns with the molecule’s engineered properties and preclinical data demonstrating prolonged intraocular residence time.

• Based on the positive Phase 1a data, Kalaris is currently conducting a Phase 1b/2, multi-ascending dose, dose-finding study evaluating four monthly loading doses of TH103. The study aims to assess the safety and efficacy of repeat doses of TH103 at different dose levels and to identify the optimal dose and regimen for potential Phase 3 development. Preliminary data from the Phase 1b/2 study is expected in the first half of 2027.

• As announced in December 2025, Kalaris completed a private placement for aggregate gross proceeds of $50.0 million.

Financial Results for the Year Ended December 31, 2025

Cash, Cash Equivalents and Marketable Securities: As of December 31, 2025, Kalaris had cash, cash equivalents and marketable securities of $118.0 million, compared with cash and cash equivalents of $1.6 million as of December 31, 2024. The increase in cash, cash equivalents and marketable securities was primarily a result of the completion of its merger with AlloVir in March 2025 and the closing of its private placement in December 2025. Kalaris expects that its cash, cash equivalents and marketable securities as of December 31, 2025 will be sufficient to fund its operations into the fourth quarter of 2027.

Research and Development Expenses: Research and development expenses were $30.8 million for the year ended December 31, 2025, compared with $45.0 million for the year ended December 31, 2024. The decrease was primarily attributable to a $32.0 million royalty obligation expense for a Royalty agreement that Kalaris entered into with Samsara BioCapital, LP in July 2024, offset by an increase in costs related to the outsourcing of manufacturing and clinical-related costs to support the Phase 1a and Phase 1b/2 clinical trials.

General and Administrative Expenses: General and administrative expenses were $15.4 million for the year ended December 31, 2025, compared with $6.7 million for the year ended December 31, 2024. The increase was primarily attributable to an increase in insurance, legal, accounting, and other professional fees and personnel related costs to support operating as a public company.

Net Loss: For the year ended December 31, 2025, net loss was $43.4 million compared with a net loss of $69.2 million for the year ended December 31, 2024. The total number of shares of common stock outstanding as of December 31, 2025 was 22,902,418.

About Kalaris

Kalaris Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases. Founded by renowned scientist Dr. Napoleone Ferrara, whose pioneering research led to the development of anti-VEGF therapy, the company is committed to advancing novel therapeutic approaches for patients with sight-threatening retinal conditions with major unmet medical needs.

For more information, visit www.kalaristx.com.

Forward Looking Statements

This press release contains “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934, as amended, that involve substantial risk and uncertainties. All statements, other than statements of historical fact, contained in this press release, including statements regarding the strategy, future operations, future financial position, projected costs, prospects, plans and objectives of management of Kalaris; the therapeutic potential of TH103 for neovascular Age-related Macular Degeneration and other exudative and neovascular retinal diseases; the anticipated timeline for reporting data from the ongoing Phase 1b/2 clinical trial of TH103; plans to advance TH103 into Phase 3 clinical trials and to develop TH103 for additional indications; plans to improve the manufacturing process for TH103; the sufficiency of Kalaris’ cash resources for the period anticipated, are forward-looking statements. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These statements are based on current expectations and beliefs of the management of Kalaris as well as assumptions made by, and information currently available to, the management of Kalaris and are subject to risks and uncertainties. There can be no assurance that future developments affecting Kalaris will be those that it has anticipated. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various important factors, including: risks associated with the clinical development and regulatory approval of TH103, including potential delays in the completion of clinical trials; expectations regarding the therapeutic benefits, clinical potential and clinical development of TH103; the timing of and Kalaris’ ability to enroll patients in clinical trials; whether results from preclinical studies and initial data from early clinical trials will be predictive of the final results of the clinical trials or future trials; dependence on third parties for the development and manufacture of TH103; risks related to the inability of Kalaris to obtain sufficient additional capital to continue to advance its product candidate; uncertainties in obtaining successful clinical results for product candidates and unexpected costs that may result therefrom; risks related to the failure to realize any value from any product candidates being developed and anticipated to be developed in light of inherent risks and difficulties involved in successfully bringing product candidates to market; the ability to obtain, maintain, and protect intellectual property rights related to product candidates; changes in regulatory requirements and government incentives; Kalaris’ competitive position and expectations regarding developments and projections relating to its competitors and any competing therapies that are or become available; the risk of involvement in current and future litigation; and such other factors as are set forth in Kalaris’ public filings with the SEC, including, but not limited to, those described under the heading “Risk Factors”. Kalaris may not actually achieve the plans, intentions or expectations disclosed in its forward-looking statements, and you should not place undue reliance on its forward-looking statements. The forward-looking statements contained in this press release are made as of the date of this press release, and Kalaris does not assume any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

Kalaris Therapeutics Investor Contact:

Corey Davis, Ph.D.

LifeSci Advisors

+1 212 915 2577

cdavis@lifesciadvisors.com

ir@kalaristx.com

Kalaris Therapeutics, Inc.

Condensed Consolidated Statements of Operations

(unaudited, in thousands, except share and per share data)

		Year Ended December 31,
		2025				2024
Operating expenses
Research and development		$	30,753			$	45,042
General and administrative			15,399				6,690
Total operating expenses			46,152				51,732
Loss from operations			(46,152	)			(51,732	)
Total other income (expense), net			2,714				(17,435	)
Net loss		$	(43,438	)		$	(69,167	)
Net loss per share, basic and diluted		$	(2.85	)		$	(51.77	)
Weighted-average shares outstanding, basic and diluted			15,267,817				1,335,925

Kalaris Therapeutics, Inc.

Condensed Consolidated Balance Sheets

(unaudited, in thousands)

		December 31, 2025				December 31, 2024
Assets
Current assets
Cash and cash equivalents and marketable securities		$	117,982			$	1,639
Other current assets			827				967
Total current assets			118,809				2,606
Other assets			2,927				3,556
Total assets		$	121,736			$	6,162
Liabilities, redeemable convertible preferred stock and stockholders’ equity (deficit)
Current liabilities		$	9,714			$	24,703
Long-term liabilities			33,208				32,076
Total liabilities			42,922				56,779
Redeemable convertible preferred stock			—				45,999
Total stockholders’ equity (deficit)			78,814				(96,616	)
Total liabilities, redeemable convertible preferred stock and stockholders’ equity (deficit)		$	121,736			$	6,162

Filing Exhibits & Attachments

4 documents

Press Releases

• EX-99.1 EX-99.1 43.4 KB

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA 2.8 KB
• EX-101 XBRL TAXONOMY EXTENSION LABEL LINKBASE 17.6 KB
• EX-101 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE 11.0 KB